NOTE: since publication of this news story, the name of Omni’s new product has been changed for legal reasons to LeanPaws.
Petcare challenger Omni has unveiled Pawzempic, a drug-free supplement designed to combat canine obesity.
Inspired by the success of human weight-loss medications, Pawzempic is the result of more than two years’ development. The non-prescription powdered supplement combines naturally derived amino acids, unique fibres and gut-friendly prebiotics and probiotics. “Together, they’re designed to increase metabolism, regulate blood sugar and promote satiety,” said Omni.
“Pawzempic has already undergone a blinded, placebo-controlled study in Norway involving veterinary assessments and monitoring,” added the vet-founded brand. “Dog owners didn’t know if their dogs were given the supplement or placebo, resulting in objective, reliable findings. The results? Nearly 80% of dogs lost weight, with virtually no side effects.”
Dr Guy Sandelowsky, practicing vet & Omni co-founder, added: “It’s incredibly encouraging to see such consistent weight loss across dogs in the trial, particularly without notable side effects. There’s a real gap between dietary advice and practical, scalable tools for weight management in pets, and we believe this supplement could be a real game-changer.”
Omni is now working with School of Veterinary Medicine and Science at the University of Nottingham to co-author a scientific paper on the subject – the findings of which are expected to be presented later this year.
Pawzempic will then be available from early 2026 (rsp: TBC), compatible with every type of diet.
It came in response to recent reports that suggested “one in two UK dogs are overweight, a statistic that carries significant consequences”, Omni said. “Excess weight not only affects mobility; it reduces overall quality of life and can even shorten a dog’s lifespan. Overweight dogs often suffer from joint pain, reduced energy, and a higher risk of more serious chronic diseases.”
In February, Omni secured an offer for £75k on Dragons’ Den, as it sought to expand its portfolio of plant-based dogfood and supplements. Sandelowsky and co-founder Shiv Sivakumar agreed to a joint investment from Deborah Meaden and Steven Bartlett in return for a 2.5% equity stake, valuing the petcare business at £3m.
No comments yet